Eli Lilly beats Novo Nordisk to China approval for first oral GLP-1 weight-loss drug

South China Morning Post - Nov 13, 2026

China has approved US pharmaceutical giant Eli Lilly’s weight-loss pill orforglipron, making it the country’s first available oral GLP-1 treatment for obesity as global drug makers seek to tap the country’s massive weight-management market. China’s National Medical Products Administration announced the approval on Thursday, saying that the once-daily pill, marketed as Foundayo, could be used for chronic weight management by obese or overweight adults. GLP-1 receptor agonists are synthetic...

Read full article

More News

About Us
Logo

In-Depth Science delivers comprehensive and compelling news and analysis on everything science and technology, seven days a week in a reader-friendly format.

Contact us: sales[at]indepthscience.com

Copyright © 2015 - 2026 In-Depth Science. All Rights Reserved.